Genelux Corporation (GNLX)
NASDAQ: GNLX · Real-Time Price · USD
2.730
+0.010 (0.37%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Genelux Revenue
Genelux had revenue of $8.00K in the twelve months ending June 30, 2026. In the year 2025, Genelux had annual revenue of $8.00K.
Revenue (ttm)
$8.00K
Revenue Growth
n/a
P/S Ratio
15,292.10
Revenue / Employee
$308
Employees
26
Market Cap
122.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.00K | - | - |
| Dec 31, 2024 | 8.00K | -162.00K | -95.29% |
| Dec 31, 2023 | 170.00K | -10.90M | -98.46% |
| Dec 31, 2022 | 11.07M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GNLX News
- 10 days ago - Genelux reports Q2 EPS (21c), consensus (20c) - TheFly
- 10 days ago - Genelux expects cash to fund operations into Q1 of 2027 - TheFly
- 10 days ago - Genelux reports Q2 EPS (21c), consensus (20c) - TheFly
- 13 days ago - Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates - GlobeNewsWire
- 14 days ago - Genelux Quarterly report: Q2 2026 - Filings
- 14 days ago - Genelux Earnings release: Q2 2026 - Filings
- 14 days ago - Genelux Slides: Corporate presentation - Filings
- 2 months ago - Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - GlobeNewsWire